

09/717789

Search results

## Freeform Search

<b>Database:</b>	<div style="border: 1px solid black; padding: 2px;">         US Pre-Grant Publication Full-Text Database          US Patents Full-Text Database          US OCR Full-Text Database          EPO Abstracts Database          JPO Abstracts Database          Derwent World Patents Index          IBM Technical Disclosure Bulletins       </div>
<b>Term:</b>	<div style="border: 1px solid black; height: 30px; width: 500px;"></div>
<b>Display:</b>	<div style="border: 1px solid black; width: 50px; text-align: center;">100</div> Documents in <b>Display Format:</b> <div style="border: 1px solid black; width: 50px; text-align: center;">-</div> Starting with Number <div style="border: 1px solid black; width: 50px; text-align: center;">1</div>
<b>Generate:</b>	<input type="radio"/> Hit List <input checked="" type="radio"/> Hit Count <input type="radio"/> Side by Side <input type="radio"/> Image

Search

Clear

Interrupt

## Search History

 DATE: Friday, March 18, 2005    [Printable Copy](#)    [Create Case](#)

<u>Set</u> <u>Name</u> side by side	<u>Query</u>	<u>Hit</u> <u>Count</u>	<u>Set</u> <u>Name</u> result set
	DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD; PLUR=YES; OP=OR		
<u>L5</u>	L4 and recombinant near5 (AAV5 or AAV near 5 or AAV near5 serotype near 5)	16	<u>L5</u>
<u>L4</u>	AAV5 or AAV near 5 or AAV near5 serotype\$ near 5	299	<u>L4</u>
<u>L3</u>	l1 and (AAV5 or aav near5 serotype near 5) near5 (p5 or protein\$ or VP1 or VP2 or VP3 or rep\$ or cap)	24	<u>L3</u>
<u>L2</u>	L1 and AAV5 near5 ITR\$	14	<u>L2</u>
<u>L1</u>	(AAV5 or aav near 5 or AAV near5 serotype near3 5) near5 vector\$	140	<u>L1</u>

END OF SEARCH HISTORY

[Generate Collection](#)[Print](#)**Search Results - Record(s) 1 through 100 of 140 returned.**

- 
- ☐ 1. [20050060762](#). 23 Sep 04. 17 Mar 05. Expression vectors. Bleck, Gregory T.. 800/8; 435/325 435/456 536/23.1 A01K067/00 C07H021/04.
- 
- ☐ 2. [20050042740](#). 21 May 04. 24 Feb 05. Methods for producing preparations of recombinant AAV virions substantially free of empty capsids. Qu, Guang, et al. 435/239; 435/456 C12N007/02 C12N015/86.
- 
- ☐ 3. [20050037497](#). 31 Mar 04. 17 Feb 05. Compounds and methods to enhance rAAV transduction. Engelhardt, John F., et al. 435/456; C12N015/861.
- 
- ☐ 4. [20050036988](#). 05 May 04. 17 Feb 05. Compositions and methods for preventing and treating liver cirrhosis. Xu, Ruian, et al. 424/93.2; 514/44 A61K048/00.
- 
- ☐ 5. [20050032219](#). 08 Sep 04. 10 Feb 05. Methods of administering vectors to synaptically connected neurons. Aubourg, Patrick, et al. 435/456; 424/93.2 A61K048/00 C12N015/861.
- 
- ☐ 6. [20050031593](#). 28 May 04. 10 Feb 05. Method for treating cancer by vector-mediated delivery of one or more anti-angiogenic or pro-apoptotic genes. Harding, Thomas, et al. 424/93.2; 435/456 A61K048/00 C12N015/86.
- 
- ☐ 7. [20050019927](#). 13 Jul 03. 27 Jan 05. DECREASING GENE EXPRESSION IN A MAMMALIAN SUBJECT IN VIVO VIA AAV-MEDIATED RNAi EXPRESSION CASSETTE TRANSFER. Hildinger, Markus, et al. 435/456; 435/375 514/44 A61K048/00 C12N015/86 C12N005/02.
- 
- ☐ 8. [20050014262](#). 08 Jun 04. 20 Jan 05. Adeno-associated virus (aav) serotype 9 sequences, vectors containing same, and uses therefor. Gao, Guangping, et al. 435/456; 435/235.1 530/350 C12N007/00 C12N015/861 C07K014/075.
- 
- ☐ 9. [20040261141](#). 21 Apr 04. 23 Dec 04. Animal model for therapy of diseases of the eye. Weber, Bernhard Heinrich Friedrich, et al. 800/18; A01K067/027.
- 
- ☐ 10. [20040258666](#). 07 Jun 04. 23 Dec 04. Gene therapy for neurometabolic disorders. Passini, Marco A., et al. 424/93.2; 514/44 A61K048/00.
- 
- ☐ 11. [20040258665](#). 04 Jun 04. 23 Dec 04. Excipients for use in adeno-associated virus pharmaceutical formulations, and pharmaceutical formulations made therewith. Sista, Hema S., et al. 424/93.2; 514/738 A61K048/00 A61K031/045.
- 
- ☐ 12. [20040253581](#). 23 Jan 04. 16 Dec 04. Transgenic animals expressing transdominant negative retroviral nucleic acids and proteins. Eakle, Kurt, et al. 435/5; 435/320.1 435/325 435/456 435/69.3 536/23.72 C12Q001/70 C07H021/02 C12N015/867.
- 
- ☐ 13. [20040248826](#). 03 Jun 03. 09 Dec 04. Treatment of cancer by in vivo gene-transfer induced TIMP-3 expression. Auricchio, Alberto, et al. 514/44; 424/93.2 A61K048/00.
-

- ☐ 14. [20040248301](#). 30 Apr 04. 09 Dec 04. Adeno-associated virus vectors with intravector heterologous terminal palindromic sequences. Engelhardt, John F., et al. 435/456; C12N015/861.
- 
- ☐ 15. [20040248262](#). 21 Jan 04. 09 Dec 04. Constructs for expressing lysosomal polypeptides. Koeberl, Dwight D., et al. 435/69.7; 435/206 435/320.1 435/325 536/23.2 C12N009/36 C07H021/04 C12P021/04.
- 
- ☐ 16. [20040248174](#). 19 Apr 04. 09 Dec 04. Compositions and methods for siRNA inhibition of angiopoietin 1 and 2 and their receptor Tie2. Reich, Samuel Jotham, et al. 435/6; 514/44 536/23.1 A61K048/00 C12Q001/68 C07H021/02.
- 
- ☐ 17. [20040235174](#). 03 Jun 04. 25 Nov 04. Aav helper plasmids for helper virus-free packaging and pseudo typification of aav vectors. Grimm, Dirk, et al. 435/457; C12N015/861.
- 
- ☐ 18. [20040235173](#). 16 Jan 04. 25 Nov 04. Production of host cells containing multiple integrating vectors by serial transduction. Bleck, Gregory T., et al. 435/456; C12N015/867.
- 
- ☐ 19. [20040234539](#). 30 Dec 03. 25 Nov 04. Nucleic acid vaccine compositions having a mammalian cd80/cd86 gene promoter driving antigen expression. Umlauf, Scott. 424/185.1; 514/44 A61K048/00 A61K039/00.
- 
- ☐ 20. [20040220129](#). 16 Jan 04. 04 Nov 04. Compositions and methods for siRNA inhibition of ICAM-1. Reich, Samuel Jotham, et al. 514/44; 536/23.1 A61K048/00 C07H021/02.
- 
- ☐ 21. [20040209364](#). 09 Jun 04. 21 Oct 04. AAV vector packaging plasmid for producing wtaav particles or pseudotyped aav particles without helper viruses, by means of a single transfection. Grimm, Dirk, et al. 435/456; 435/235.1 435/457 C12N007/01 C12N015/861.
- 
- ☐ 22. [20040209245](#). 11 Mar 04. 21 Oct 04. Production of pseudotyped recombinant AAV virions. Snyder, Richard O., et al. 435/5; 435/235.1 435/456 435/69.3 530/350 536/23.72 C12Q001/70 C07H021/04 C12N007/00 C12N015/861 C07K014/075.
- 
- ☐ 23. [20040204379](#). 16 Jan 04. 14 Oct 04. Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases. Cheng, Seng H., et al. 514/44; A61K048/00.
- 
- ☐ 24. [20040197895](#). 02 May 03. 07 Oct 04. Packaging lines for generation of high titers or recombinant aav vectors. Kotin, Robert M., et al. 435/235.1; 435/348 435/456 C12N007/00 C12N005/06 C12N015/861.
- 
- ☐ 25. [20040192630](#). 18 Feb 04. 30 Sep 04. Vectors having both isoforms of beta-hexosaminidase and uses of the same. Kyrkanides, Stephanos. 514/44; A61K048/00.
- 
- ☐ 26. [20040191762](#). 04 Feb 04. 30 Sep 04. Method for purification of viral vectors having proteins which bind sialic acid. Wilson, James M, et al. 435/5; 530/350 530/395 C12Q001/70 C07K014/075.
- 
- ☐ 27. [20040191221](#). 20 May 02. 30 Sep 04. Methods of treating skeletal disorders using recombinant adeno-associated virus virions. Ozawa, Keiya, et al. 424/93.2; 424/93.1 435/455 A01N063/00 A01N065/00 A61K048/00 C12N015/63 C12N015/85 C12N015/87.
- 
- ☐ 28. [20040161409](#). 06 Oct 03. 19 Aug 04. Induction of immune response to antigens expressed by

recombinant adeno-associated virus. Kurtzman, Gary J., et al. 424/93.2; 435/456 A61K048/00 C12N015/861.

---

❑ 29. [20040142416](#). 30 Apr 03. 22 Jul 04. Treatment for phenylketonuria. Laipis, Philip J., et al. 435/69.1; 435/191 435/320.1 435/325 435/456 536/23.2 C07H021/04 C12N009/06 C12N015/861.

---

❑ 30. [20040110266](#). 17 May 02. 10 Jun 04. Scalable purification of AAV2, AAV4 or AAV5 using ion-exchange chromatography. Chiorini, John A., et al. 435/239; C12N007/02.

---

❑ 31. [20040101514](#). 01 May 03. 27 May 04. High transgene expression of a pseudotyped adeno-associated virus type. Liu, Yuhong, et al. 424/93.2; 435/235.1 435/457 A61K048/00 C12N007/01 C12N015/861.

---

❑ 32. [20040091966](#). 19 May 03. 13 May 04. Polypeptide regulation by conditional inteins. Zeidler, Martin, et al. 435/69.1; 435/320.1 435/325 435/455 530/350 536/23.5 C12P021/02 C07H021/04 C12P021/06 C07K014/47 C12N015/85.

---

❑ 33. [20040087028](#). 24 Sep 03. 06 May 04. Ecdysone-inducible adeno-associated virus expression vectors. Cunningham, Janet. 435/456; 435/235.1 C12N015/861 C12N007/00.

---

❑ 34. [20040086490](#). 20 Nov 03. 06 May 04. AAV4 vector and uses thereof. Chiorini, John A., et al. 424/93.2; 435/235.1 435/320.1 435/456 A61K048/00 C12N007/00 C12N015/861.

---

❑ 35. [20040072351](#). 30 Apr 03. 15 Apr 04. Methods and compositions for expressing a nucleic acid in a dendritic cell. Womer, Karl L., et al. 435/456; 424/93.2 A61K048/00 C12N015/861.

---

❑ 36. [20040057933](#). 30 Oct 03. 25 Mar 04. Adeno-associated virus serotype 1 nucleic acid sequences, vectors and host cells containing same. Wilson, James M., et al. 424/93.2; 435/456 536/23.1 A61K048/00 C07H021/04 C12N015/861.

---

❑ 37. [20040052764](#). 25 Oct 02. 18 Mar 04. Recombinant aav vectors with aav5 capsids and aav5 vectors pseudotyped in heterologous capsids. Hildinger, Markus, et al. 424/93.2; 435/456 A61K048/00 C12N015/861.

---

❑ 38. [20040048822](#). 07 Oct 03. 11 Mar 04. Nucleic acid immunization. Harrison, Juan. 514/44; 424/490 A61K048/00 A61K009/16 A61K009/50.

---

❑ 39. [20040018627](#). 30 Jul 03. 29 Jan 04. High-efficiency AAV helper functions. Natsoulis, Georges, et al. 435/456; 435/235.1 435/325 C12N015/861 C12N007/00.

---

❑ 40. [20030228282](#). 25 Apr 03. 11 Dec 03. Adeno-associated virus (AAV) serotype 8 sequences, vectors containing same, and uses therefor. Gao, Guangping, et al. 424/93.2; 435/235.1 435/372 435/456 530/350 536/23.72 A61K048/00 C07H021/04 C12N007/00 C12N015/861 C07K014/075 C12N005/08.

---

❑ 41. [20030224415](#). 26 Mar 03. 04 Dec 03. Selection free growth of host cells containing multiple integrating vectors. Bremel, Robert D., et al. 435/6; 435/320.1 435/325 435/456 435/69.1 435/7.92 530/395 536/23.5 C12Q001/68 G01N033/53 G01N033/537 G01N033/543 C07H021/04 C07K014/02 C12P021/02 C12N005/06 C12N015/867.

---

❑ 42. [20030223971](#). 13 Jan 03. 04 Dec 03. Gene therapy for the treatment of solid tumors using recombinant adeno-associated virus vectors. Kurtzman, Gary J., et al. 424/93.21; 435/235.1 435/456

514/44 A61K048/00 C12N007/00 C12N015/861.

---

☐ 43. [20030223966](#). 30 Apr 03. 04 Dec 03. Treatment for pompe disease. Fraites, Thomas J. JR., et al. 424/93.2; 435/456 A61K048/00 C12N015/861.

---

☐ 44. [20030219415](#). 23 May 03. 27 Nov 03. Methods for delivering DNA to muscle cells using recombinant adeno-associated virus virions. Podsakoff, Gregory M., et al. 424/93.2; 435/235.1 435/456 A61K048/00 C12N007/00 C12N015/861.

---

☐ 45. [20030219414](#). 22 Apr 03. 27 Nov 03. Recombinant adeno-associated virus virions for the treatment of lysosomal disorders. Podsakoff, Gregory, et al. 424/93.2; 435/456 A61K048/00 C12N015/861.

---

☐ 46. [20030206889](#). 10 Jun 03. 06 Nov 03. Methods of treating anemia using recombinant adeno-associated virus virions. Podsakoff, Gregory M., et al. 424/93.2; 435/456 A61K048/00 C12N015/861.

---

☐ 47. [20030198620](#). 16 Apr 02. 23 Oct 03. Method of treating amino acid metabolic disorders using recombinant adeno-associated virus virions. Ozawa, Keiya, et al. 424/93.2; 435/235.1 435/456 A61K048/00 C12N007/00 C12N015/861.

---

☐ 48. [20030190308](#). 19 Mar 02. 09 Oct 03. Adjuvant. Braun, Ralph P., et al. 424/93.2; 514/292 514/44 A61K048/00 A61K031/4745.

---

☐ 49. [20030185848](#). 15 Dec 00. 02 Oct 03. Methods and compositions for vaccination comprising nucleic acid and/or polypeptide sequences of Chlamydia psittaci. Johnston, Stephen A., et al. 424/190.1; 435/252.3 435/320.1 435/69.3 514/44 530/350 536/23.7 A61K039/02 A61K048/00 C07H021/04 C12N001/21 C12N015/74 C07K014/295.

---

☐ 50. [20030185835](#). 19 Mar 02. 02 Oct 03. Adjuvant for vaccines. Braun, Ralph P.. 424/184.1; 424/489 536/23.1 C07H021/02 C07H021/04 A61K039/00 A61K009/14 A61K039/38.

---

☐ 51. [20030170896](#). 19 Jun 02. 11 Sep 03. Accessory functions for use in recombinant AAV virion production. Colosi, Peter C.. 435/456; 435/235.1 435/320.1 C12N007/00 C12N015/861.

---

☐ 52. [20030162733](#). 26 Nov 01. 28 Aug 03. Nucleic acid adjuvants. Haynes, Joel R., et al. 514/44; 435/375 A61K048/00 C12N005/00.

---

☐ 53. [20030148952](#). 18 Oct 02. 07 Aug 03. Methods and materials for the recruitment of endothelial cells. Crombleholme, Timothy M.. 514/12; 424/93.2 514/44 A61K048/00 A61K038/24.

---

☐ 54. [20030148506](#). 13 Aug 02. 07 Aug 03. Production of adeno-associated virus in insect cells. Kotin, Robert M., et al. 435/320.1; 424/199.1 435/235.1 435/239 A61K039/12 C12N007/00 C12N007/01 C12N007/02 C12N015/00 C12N015/09 C12N015/63 C12N015/70 C12N015/74.

---

☐ 55. [20030147855](#). 13 Jan 03. 07 Aug 03. Adiponectin gene therapy. Zolotukhin, Sergei, et al. 424/93.2; 435/235.1 435/456 A61K048/00 C12N007/00 C12N015/861.

---

☐ 56. [20030147853](#). 14 Mar 02. 07 Aug 03. Recombinant adeno-associated virus-mediated gene transfer via retroductal infusion of virions. McClelland, Alan, et al. 424/93.2; 435/235.1 435/456 A61K048/00 C12N015/861 C12N007/00.

---

57. [20030138772](#). 12 Nov 02. 24 Jul 03. Method of detecting and/or identifying adeno-associated virus (AAV) sequences and isolating novel sequences identified thereby. Gao, Guangping, et al. 435/5; 424/93.2 435/456 435/6 530/350 C12Q001/68 C12Q001/70 A61K048/00 C12N015/861 C07K014/075.
- 
58. [20030124718](#). 20 May 02. 03 Jul 03. Vaccine composition. Fuller, Deborah, et al. 435/320.1; 424/199.1 424/225.1 435/226 435/372 435/6 435/69.1 536/23.2 C12Q001/68 C07H021/04 C12N009/64 C12P021/02 C12P021/06 A61K039/12 C12N015/00 C12N015/09 C12N015/63 C12N015/70 C12N015/74 C12N005/08 A61K039/29.
- 
59. [20030119191](#). 20 Sep 02. 26 Jun 03. Compositions and methods for helper-free production of recombinant adeno-associated viruses. Gao, Guangping, et al. 435/456; 435/235.1 C12N015/861 C12N007/00.
- 
60. [20030108920](#). 09 Sep 02. 12 Jun 03. Tumor suppressor-like proteins that bind IGFBP2. Zhang, Wei, et al. 435/6; 435/320.1 435/325 435/69.1 435/7.23 514/12 514/44 530/350 536/23.2 800/18 A61K048/00 A61K038/17 A01K067/027 C12Q001/68 G01N033/574 C12P021/02 C12N005/06 C07K014/47.
- 
61. [20030108525](#). 10 Jan 03. 12 Jun 03. Excipients for use in adeno-associated virus pharmaceutical formulations, and pharmaceutical formulations made therewith. Sista, Hema S., et al. 424/93.2; 514/723 514/738 A61K048/00 A61K031/08 A61K031/045.
- 
62. [20030103941](#). 09 Oct 02. 05 Jun 03. Materials and methods for preventing or reducing scar formation. Crombleholme, Timothy M., et al. 424/93.2; 435/456 514/44 A61K048/00 C12N015/861 C12N015/867 C12N015/869.
- 
63. [20030103939](#). 12 Jul 02. 05 Jun 03. Pseudotyped adeno-associated viruses and uses thereof. Engelhardt, John F., et al. 424/93.2; 435/235.1 435/320.1 435/456 514/44 A61K048/00 C12N007/00 C12N015/861.
- 
64. [20030092882](#). 29 Jun 01. 15 May 03. Host cells containing multiple integrating vectors. Bremel, Robert D., et al. 530/350; 435/320.1 435/325 435/69.1 C07K014/435 C12P021/02 C12N005/06 C12N015/00.
- 
65. [20030082811](#). 29 Jun 01. 01 May 03. Adenovirus E4 protein variants for virus production. Orlando, Joseph S., et al. 435/456; 435/235.1 435/369 C12N015/861 C12N007/00 C12N005/08.
- 
66. [20030073659](#). 15 Jul 02. 17 Apr 03. Adeno associated virus and adenovirus chimeric recombinant viruses useful for the integration of foreign genetic information into the chromosomal DNA of target cells. Einerhand, Markus Peter, et al. 514/44; 424/93.2 435/320.1 435/456 A61K048/00 C12N015/861.
- 
67. [20030053990](#). 26 Jul 02. 20 Mar 03. Virus vectors and methods of making and administering the same. Rabinowitz, Joseph E., et al. 424/93.2; 435/235.1 435/456 435/457 A61K048/00 C12N007/00 C12N015/861.
- 
68. [20030044963](#). 13 May 02. 06 Mar 03. Compositions and methods for producing recombinant adeno-associated virus. Mejza, Stephen, et al. 435/239; 424/199.1 424/233.1 435/235.1 435/320.1 A61K039/12 A61K039/23 A61K039/235 C12N007/00 C12N007/01 C12N007/02 C12N015/00 C12N015/09 C12N015/63 C12N015/70 C12N015/74.
-

69. [20030013189](#). 17 Sep 01. 16 Jan 03. Compositions and methods useful for non-invasive delivery of therapeutic molecules to the bloodstream. Wilson, James M., et al. 435/320.1; 424/199.1 424/233.1 424/278.1 435/235.1 A61K039/12 A61K039/23 A61K039/235 C12N007/00 C12N007/01 A61K045/00 A61K047/00 C12N015/00 C12N015/09 C12N015/63 C12N015/70 C12N015/74.
- 
70. [20030003583](#). 10 Jun 02. 02 Jan 03. Regulation of transgene expression following AAV transduction. Hirsch, Raphael, et al. 435/456; 424/93.2 435/184 435/6 A61K048/00 C12N015/861 C12Q001/68 C12N009/99.
- 
71. [20020187127](#). 25 Apr 02. 12 Dec 02. Methods of increasing distribution of nucleic acids. Bankiewicz, Krys. 424/93.2; 514/56 A61K048/00 A61K031/727.
- 
72. [20020183272](#). 17 Dec 01. 05 Dec 02. Methods and compositions for vaccination comprising nucleic acid and/or polypeptide sequences of chlamydia. Johnston, Stephen A., et al. 514/44; 536/23.7 A61K048/00 C07H021/04.
- 
73. [20020182595](#). 29 Apr 02. 05 Dec 02. Method of identifying cellular regulators of adeno-associated virus (AAV). Weitzman, Matthew D., et al. 435/5; 435/6 C12Q001/70 C12Q001/68.
- 
74. [20020177222](#). 10 Aug 01. 28 Nov 02. Replication competent AAV helper functions. Li, Sikun. 435/320.1; 435/235.1 435/456 435/5 536/23.1 C12N015/861 C07H021/04 C12N007/00 C12Q001/70 C07H021/02 C12N007/01 C12N015/00 C12N015/09 C12N015/63 C12N015/70 C12N015/74 C12N015/86.
- 
75. [20020155610](#). 11 Feb 02. 24 Oct 02. High-efficiency wild-type-free AAV helper functions. Colosi, Peter. 435/457; 435/235.1 435/325 C12N015/861 C12N007/00.
- 
76. [20020155608](#). 01 Oct 01. 24 Oct 02. Methods for delivering DNA to muscle cells using recombinant adeno-associated virus virions. Podsakoff, Gregory M., et al. 435/456; 424/93.21 435/235.1 435/320.1 C12N015/861 C12N007/01 A61K048/00.
- 
77. [20020147172](#). 05 Mar 02. 10 Oct 02. Methods for delivering DNA to muscle cells using recombinant adeno-associated virus vectors. Podsakoff, Gregory M., et al. 514/44; 435/456 A61K048/00 C12N015/861.
- 
78. [20020141980](#). 21 Jun 01. 03 Oct 02. Convection-enhanced delivery of AAV vectors. Bankiewicz, Krys, et al. 424/93.21; 424/93.6 A61K048/00.
- 
79. [20020141979](#). 10 Apr 01. 03 Oct 02. Methods and compositions for STAT-1 conferred resistance to immunotoxicity. Chen, Guoxun, et al. 424/93.21; 435/366 435/456 A61K048/00 C12N005/08 C12N015/86.
- 
80. [20020119541](#). 09 Aug 01. 29 Aug 02. Tumor suppressor CAR-1. Killary, Ann, et al. 435/184; 435/320.1 435/325 435/69.2 536/23.2 C07H021/04 C12N009/99 C12P021/02 C12N005/06.
- 
81. [20020115189](#). 18 Dec 01. 22 Aug 02. High-efficiency AAV helper functions. Natsoulis, Georges, et al. 435/235.1; 435/325 435/456 C12N007/00 C12N015/86 C12N005/00.
- 
82. [20020111324](#). 17 Aug 01. 15 Aug 02. Adeno-associated virus-mediated delivery of angiogenic factors. Ozawa, Keiya, et al. 514/44; 424/93.2 424/93.6 435/456 A61K048/00 C12N015/861.
-

83. [20020106729](#). 29 Jun 01. 08 Aug 02. Expression vectors. Bleck, Gregory T.. 435/69.1; 435/320.1 435/325 435/456 435/6 536/23.2 C12P021/02 C12N005/06 C12N015/867 C12Q001/68 C07H021/04.
- 
84. [20020106381](#). 13 Jun 01. 08 Aug 02. Methods for administering recombinant adeno-associated virus virions to humans previously exposed to adeno-associated virus. High, Katherine A.. 424/233.1; 424/93.21 A61K048/00 A61K039/235.
- 
85. [20020102243](#). 16 May 01. 01 Aug 02. Induction of immune response to antigens expressed by recombinant adeno-associated virus. Kurtzman, Gary J., et al. 424/93.21; 435/235.1 435/320.1 435/456 A61K048/00 C12N007/00 C12N015/861.
- 
86. [20020081721](#). 12 Dec 97. 27 Jun 02. AAV SPLIT-PACKAGING GENES AND CELL LINES COMPRISING SUCH GENES FOR USE IN THE PRODUCTION OF RECOMBINANT AAV VECTORS. ALLEN, JAMES M., et al. 435/325; C12N005/00 C12N005/02.
- 
87. [20020076754](#). 20 Apr 01. 20 Jun 02. Overcoming AAV vector size limitation through viral DNA hetero-dimerization. Sun, Liangwu, et al. 435/69.1; C12P021/06.
- 
88. [20020068713](#). 22 May 01. 06 Jun 02. Genetic engineering of vascular grafts to resist disease. Rade, Jeffrey J., et al. 514/44; 424/93.21 A61K048/00.
- 
89. [20020058325](#). 26 Jan 01. 16 May 02. Recombinant AAV packaging systems. Hardy, Stephen F.. 435/235.1; 424/233.1 435/325 536/23.72 C12N007/01 C12N005/06 C07H021/04 A61K039/23.
- 
90. [20020052485](#). 20 Apr 01. 02 May 02. Polynucleotides for use in recombinant adeno-associated virus virion production. Colosi, Peter. 536/23.1; 435/235.1 C07H021/02 C07H021/04 C12N007/00.
- 
91. [20020045264](#). 13 Mar 01. 18 Apr 02. Production of chimeric capsid vectors. During, Matthew J., et al. 435/456; 435/235.1 435/320.1 C12N015/861 C12N007/01.
- 
92. [20020019050](#). 05 Apr 01. 14 Feb 02. Compositions and methods for helper-free production of recombinant adeno-associated viruses. Gao, Guangping, et al. 435/456; 435/235.1 C12N015/861 C12N007/01.
- 
93. [20010034062](#). 09 Feb 01. 25 Oct 01. Antibody gene therapy with adeno-associated viral vectors. Koenig, Scott. 435/456; 424/93.21 435/320.1 435/325 A61K048/00 C12N015/861 C12N005/10.
- 
94. [20010001661](#). 04 Jan 01. 24 May 01. Methods for delivering DNA to the bloodstream using recombinant adeno-associated virus vectors. Podsakoff, Gregory M., et al. 424/93.2; 514/44 A61K031/70 A01N043/04.
- 
95. [6855314](#). 22 Mar 00; 15 Feb 05. [AAV5 vector](#) for transducing brain cells and lung cells. Chiorini; John A., et al. 424/93.2; 424/93.1 424/93.6 435/320.1 435/455 514/44. A01N06300 A01N06500 A01N04304 C12N01563 C12N01585.
- 
96. [6852510](#). 29 Jun 01; 08 Feb 05. Host cells containing multiple integrating vectors. Bremel; Robert D., et al. 435/69.1; 435/325 435/352 435/358 435/455 435/456 435/465 435/473. C12N01509 C12N00510 C12N01563 C12N015867.
-



☐ 97. 6844192. 29 Jun 01; 18 Jan 05. Adenovirus E4 protein variants for virus production. Orlando; Joseph S., et al. 435/456; 435/235.1 435/320.1 435/325 435/366 435/369 435/455 435/457 435/69.1 536/23.1 536/23.72. C12N005/10 C12N015/63 C12N015/861 C12N015/864.

☐ 98. 6764845. 10 Jan 03; 20 Jul 04. Excipients for use in adeno-associated virus pharmaceutical formulations, and pharmaceutical formulations made therewith. Sista; Hema S., et al. 435/235.1; 424/278.1. C12N007/00.

☐ 99. 6759050. 02 Dec 99; 06 Jul 04. Excipients for use in adeno-associated virus pharmaceutical formulations, and pharmaceutical formulations made therewith. Sista; Hema S., et al. 424/199.1; 424/204.1 424/233.1 424/278.1 424/93.2. A61K039/12.

☐ 100. 6723551. 13 Aug 02; 20 Apr 04. Production of adeno-associated virus in insect cells. Kotin; Robert M., et al. 435/235.1; 435/320.1 435/5 435/6 435/69.1 435/69.7 536/23.72. C12N007/00 C12N015/00 C12Q001/70 C12P021/06 C07H021/04.

[Generate Collection](#)[Print](#)

Terms	Documents
(AAV5 or aav near 5 or AAV near5 serotype near3 5) near5 vector\$	140

[Prev Page](#)[Next Page](#)[Go to Doc#](#)

**PALM INTRANET**Day : Friday  
Date: 3/18/2005

Time: 13:08:04

## Inventor Name Search

Enter the **first few letters** of the Inventor's Last Name.  
Additionally, enter the **first few letters** of the Inventor's First name.

**Last Name****First Name**

To go back use Back button on your browser toolbar.

Back to [PALM](#) | [ASSIGNMENT](#) | [OASIS](#) | [Home page](#)



Day : Friday  
Date: 3/18/2005

Time: 13:08:04

## Inventor Name Search

Enter the **first few letters** of the Inventor's Last Name.  
Additionally, enter the **first few letters** of the Inventor's First name.

**Last Name**

**First Name**

To go back use Back button on your browser toolbar.

Back to [PALM](#) | [ASSIGNMENT](#) | [OASIS](#) | [Home page](#)